Unknown

Dataset Information

0

Regulation of hypoxia-induced autophagy in glioblastoma involves ATG9A.


ABSTRACT: Hypoxia is negatively associated with glioblastoma (GBM) patient survival and contributes to tumour resistance. Anti-angiogenic therapy in GBM further increases hypoxia and activates survival pathways. The aim of this study was to determine the role of hypoxia-induced autophagy in GBM.Pharmacological inhibition of autophagy was applied in combination with bevacizumab in GBM patient-derived xenografts (PDXs). Sensitivity towards inhibitors was further tested in vitro under normoxia and hypoxia, followed by transcriptomic analysis. Genetic interference was done using ATG9A-depleted cells.We find that GBM cells activate autophagy as a survival mechanism to hypoxia, although basic autophagy appears active under normoxic conditions. Although single agent chloroquine treatment in vivo significantly increased survival of PDXs, the combination with bevacizumab resulted in a synergistic effect at low non-effective chloroquine dose. ATG9A was consistently induced by hypoxia, and silencing of ATG9A led to decreased proliferation in vitro and delayed tumour growth in vivo. Hypoxia-induced activation of autophagy was compromised upon ATG9A depletion.This work shows that inhibition of autophagy is a promising strategy against GBM and identifies ATG9 as a novel target in hypoxia-induced autophagy. Combination with hypoxia-inducing agents may provide benefit by allowing to decrease the effective dose of autophagy inhibitors.

SUBMITTER: Abdul Rahim SA 

PROVIDER: S-EPMC5590001 | biostudies-literature | 2017 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications


<h4>Background</h4>Hypoxia is negatively associated with glioblastoma (GBM) patient survival and contributes to tumour resistance. Anti-angiogenic therapy in GBM further increases hypoxia and activates survival pathways. The aim of this study was to determine the role of hypoxia-induced autophagy in GBM.<h4>Methods</h4>Pharmacological inhibition of autophagy was applied in combination with bevacizumab in GBM patient-derived xenografts (PDXs). Sensitivity towards inhibitors was further tested in  ...[more]

Similar Datasets

| S-EPMC4747177 | biostudies-literature
| S-EPMC3319869 | biostudies-literature
| S-EPMC6607583 | biostudies-literature
| S-EPMC8526012 | biostudies-literature
| S-EPMC5943347 | biostudies-literature
| S-EPMC8605025 | biostudies-literature
| S-EPMC5646326 | biostudies-literature
| S-EPMC7888711 | biostudies-literature
| S-EPMC1402310 | biostudies-literature
| S-EPMC4987255 | biostudies-literature